PD-L1 expression on melanoma cells has been the first candidate as a biomarker foranti-PD-1 drugs, but in melanoma it has no established role: many studies evidenced ahigh proportion of objective response in patients that resulted PDL1 negative; alsoPFS and OS resulted improved irrespective of PDL1 expression. Here, PDCD1 is linked to melanoma.